TISIDB

Summary
Symbol	ACPP
Name	acid phosphatase, prostate
Aliases	ACP3; ACP-3; prostatic acid phosphatase; TMPase; prostatic acid phosphotase; thiamine monophosphatase
Chromosomal Location	3q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Isoform 1: Secreted ; SUBCELLULAR LOCATION: Isoform 2: Cell membrane Single-pass type I membrane protein Lysosome membrane Single-pass type I membrane protein Note=Appears to shuttle between the cell membrane and intracellular vesicles. Colocalizes with FLOT1 at cell membrane and in intracellular vesicles (PubMed:17638863). Colocalizes with LAMP2 on the lysosome membrane (PubMed:17897319).
Domain	PF00328 Histidine phosphatase superfamily (branch 2)
Function	A non-specific tyrosine phosphatase that dephosphorylates a diverse number of substrates under acidic conditions (pH 4-6) including alkyl, aryl, and acyl orthophosphate monoesters and phosphorylated proteins. Has lipid phosphatase activity and inactivates lysophosphatidic acid in seminal plasma.; FUNCTION: Isoform 2: the cellular form also has ecto-5'-nucleotidase activity in dorsal root ganglion (DRG) neurons. Generates adenosine from AMP which acts as a pain suppressor. Acts as a tumor suppressor of prostate cancer through dephosphorylation of ERBB2 and deactivation of MAPK-mediated signaling.

> Gene Ontology [ TOP ]
Biological Process	GO:0001973 adenosine receptor signaling pathway GO:0006144 purine nucleobase metabolic process GO:0006766 vitamin metabolic process GO:0006767 water-soluble vitamin metabolic process GO:0006772 thiamine metabolic process GO:0006790 sulfur compound metabolic process GO:0008277 regulation of G-protein coupled receptor protein signaling pathway GO:0009112 nucleobase metabolic process GO:0009116 nucleoside metabolic process GO:0009119 ribonucleoside metabolic process GO:0016311 dephosphorylation GO:0019233 sensory perception of pain GO:0031644 regulation of neurological system process GO:0035587 purinergic receptor signaling pathway GO:0035588 G-protein coupled purinergic receptor signaling pathway GO:0042278 purine nucleoside metabolic process GO:0042723 thiamine-containing compound metabolic process GO:0044057 regulation of system process GO:0045745 positive regulation of G-protein coupled receptor protein signaling pathway GO:0046085 adenosine metabolic process GO:0046128 purine ribonucleoside metabolic process GO:0051930 regulation of sensory perception of pain GO:0051931 regulation of sensory perception GO:0060167 regulation of adenosine receptor signaling pathway GO:0060168 positive regulation of adenosine receptor signaling pathway GO:0072527 pyrimidine-containing compound metabolic process GO:1901657 glycosyl compound metabolic process
Molecular Function	GO:0003993 acid phosphatase activity GO:0008252 nucleotidase activity GO:0008253 5'-nucleotidase activity GO:0016791 phosphatase activity GO:0042131 thiamine phosphate phosphatase activity GO:0042578 phosphoric ester hydrolase activity GO:0052642 lysophosphatidic acid phosphatase activity
Cellular Component	GO:0005765 lysosomal membrane GO:0030175 filopodium GO:0098852 lytic vacuole membrane GO:0098858 actin-based cell projection

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-6798695: Neutrophil degranulation

Summary
Symbol	ACPP
Name	acid phosphatase, prostate
Aliases	ACP3; ACP-3; prostatic acid phosphatase; TMPase; prostatic acid phosphotase; thiamine monophosphatase
Chromosomal Location	3q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ACPP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between ACPP and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
23152566	Prostate carcinoma	Promote immunity	Using samples from prostate cancer patients immunized with a DNA vaccine encoding prostatic acid phosphatase (PAP) and a trans-vivo delayed-type hypersensitivity (tvDTH) assay, we found that the detection of PAP-specific effector responses after immunization was prevented by the activity of PAP-specific regulatory cells.
24338683	Prostate Carcinoma	Promote immunity	Prostatic acid phosphatase (PAP) is a prostate-specific protein overexpressed in 95% of prostate tumours. The PAP-114-128 epitope elicits CD4(+) and CD8(+) T-cell-specific responses in C57BL/6 mice. Furthermore, when immunised in a DNA vector format (ImmunoBody®), PAP-114-128 prevents and reduces the growth of transgenic adenocarcinoma of mouse prostate-C1 prostate cancer cell-derived tumours in both prophylactic and therapeutic settings. This anti-tumour effect is associated with infiltration of CD8(+) tumour-infiltrating lymphocytes and the generation of high avidity T cells secreting elevated levels of IFN-γ.

Summary
Symbol	ACPP
Name	acid phosphatase, prostate
Aliases	ACP3; ACP-3; prostatic acid phosphatase; TMPase; prostatic acid phosphotase; thiamine monophosphatase
Chromosomal Location	3q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ACPP in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ACPP
Name	acid phosphatase, prostate
Aliases	ACP3; ACP-3; prostatic acid phosphatase; TMPase; prostatic acid phosphotase; thiamine monophosphatase
Chromosomal Location	3q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ACPP in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.121	0.872
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.372	0.265
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.795	0.444
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.242	0.605
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.279	0.826
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.194	0.898
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.922	0.163
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.873	0.367
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	1.064	0.293
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.127	0.847
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.404	0.64
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.151	0.44

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ACPP in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	1.4	6	0.177
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	1.7	5.7	0.231
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	5.9	-1.1	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	ACPP
Name	acid phosphatase, prostate
Aliases	ACP3; ACP-3; prostatic acid phosphatase; TMPase; prostatic acid phosphotase; thiamine monophosphatase
Chromosomal Location	3q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ACPP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ACPP
Name	acid phosphatase, prostate
Aliases	ACP3; ACP-3; prostatic acid phosphatase; TMPase; prostatic acid phosphotase; thiamine monophosphatase
Chromosomal Location	3q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ACPP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ACPP. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ACPP
Name	acid phosphatase, prostate
Aliases	ACP3; ACP-3; prostatic acid phosphatase; TMPase; prostatic acid phosphotase; thiamine monophosphatase
Chromosomal Location	3q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ACPP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ACPP
Name	acid phosphatase, prostate
Aliases	ACP3; ACP-3; prostatic acid phosphatase; TMPase; prostatic acid phosphotase; thiamine monophosphatase
Chromosomal Location	3q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ACPP expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ACPP
Name	acid phosphatase, prostate
Aliases	ACP3; ACP-3; prostatic acid phosphatase; TMPase; prostatic acid phosphotase; thiamine monophosphatase
Chromosomal Location	3q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ACPP and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ACPP
Name	acid phosphatase, prostate
Aliases	ACP3; ACP-3; prostatic acid phosphatase; TMPase; prostatic acid phosphotase; thiamine monophosphatase
Chromosomal Location	3q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ACPP collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting ACPP.

ID	Name	Drug Type	Targets	#Targets
DB03390	N-Propyl-Tartramic Acid	Small Molecule	ACPP	1
DB03577	Alpha-Benzyl-Aminobenzyl-Phosphonic Acid	Small Molecule	ACPP	1
DB06688	Sipuleucel-T	Biotech	ACPP	1

Browse ACPP